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BACKGROUND: Some patients with endometriosis are candidates for sympathectomy of the superior hypogastric
plexus. The objective of this paper is to describe our technique of laparoscopic presacral neurolysis for sympath-
ectomy and to report 1 year results of the ®rst 15 cases. METHODS: To achieve this objective in a prospective
observational study of 1 year follow-up; we performed laparoscopic presacral chemical neurolysis with phenol in 15
patients with pelvic pain and minimal±moderate endometriosis. The main outcome measures were: the impact of
treatment on pelvic symptom resolution, non-opioid analgesic consumption during menses, sexual performance and
observed complications and side effects during 1 year follow-up. RESULTS: We noted a signi®cant reduction in
total pelvic symptom score as compared with baseline mean (SD) of 9.04 (1.2). The mean difference [95% con®dence
interval (CI)] of reduction was 5.7 (4.9±6.5), 5.8 (5.0±6.6) and 5.8 (4.9±6.6) from the baseline at the 3rd, 6th and 12th
postoperative month (P < 0.001). We observed a signi®cant improvement in Sabbatberg Sexual Rating Scale as
compared with baseline mean (SD) of 30.9 (4.3). The mean difference (95% CI) of increase was 33.4 (30.3±36.4),
33.2 (30.1±36.2) and 33.2 (30.1±36.3) from the baseline at the 3rd, 6th and 12th postoperative month. We observed a
signi®cant reduction in analgesic consumption during menses in terms of total naproxen sodium tablets as compared
with baseline mean (SD) of 8.9 (1.1). The mean difference (95% CI) of reduction in the total number of naproxen
sodium 250 mg tablets was 6.5 (5.5±7.5), 6.7 (5.7±7.7) and 6.6 (5.6±7.6) from the baseline at the 3rd, 6th and 12th
postoperative month. The most common side effect was constipation. CONCLUSION: Laparoscopic presacral
neurolysis is feasible and simple. More data is needed to support its ef®cacy and safety.
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Introduction
Hypogastric plexus is of surgical importance in gynaecology to
relieve chronic pelvic pain. In 1990 Perez has shown that
presacral neurectomy is feasible by laparoscopy (Perez, 1990).
Since then, laparoscopic presacral neurectomy has been
extensively studied and considered as an effective technique
for the treatment of chronic pelvic pain and dysmenorrhea in
selected cases (Kwok et al., 2001). The current trend is to
recommend laparoscopic presacral neurectomy in patients
suffering from midline pain. However laparoscopic presacral
neurectomy is an eclectic operation, it demands very signi®-
cant surgical skills and expertise from the surgeon. Even in the
hands of experienced surgeons it is open to vascular and
lymphatic complications because of the vicinity of great
vessels and lymphatic channels (Chen and Soong, 1997; Chen
et al., 1998; Kwok et al., 2001).
In 1990 it was shown by anaesthesiologists that transcuta-
neous neurolysis of the superior hypogastric plexus is effective
and safe in relieving pelvic cancer pain (Plancarte et al., 1990).
In the following years the indications expanded and included
benign pathologies (de Leon-Casasola, 2000).
Pain syndromes are caused by activation of nociceptors and
transmission of signals in pain pathways. Thus they are
expected to respond to interruption or modulation of that
transmission at any level above the site of activation. Chemical
neurolysis destructs the microscopic neural architecture, and
therefore interrupts the transmission function of the nerves.
Neurectomy is the surgical procedure that cuts and removes the
nerve ®bres to interrupt transmission. The superior hypogastric
plexus is the main pathway of neural transmission from the
pelvis. While in neurectomy the plexus is exposed and the
nerves are either cut or excised to interrupt the neural input, in
neurolysis their microscopic neural architecture is chemically
destroyed to interrupt the neural input.
In 1999 we decided to use chemical neurolysis via
laparoscopy in order to treat recurrent and unbearable pelvic
pain of minimal and mild endometriosis. It seemed very
attractive to us because of the potential simplicity and
effectiveness of the procedure.
The aim of this paper is to describe our technique of
laparoscopic presacral neurolysis and to report 1-year results of
the ®rst 15 prospectively followed cases on symptom
Human Reproduction Vol.18, No.3 pp. 588±592, 2003 DOI: 10.1093/humrep/deg127
588 ã European Society of Human Reproduction and Embryology
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article/18/3/588/626090 by Pam
ukkale U
niversity user on 05 O
ctober 2020
resolution, non-opioid analgesic consumption during menses,
sexual performance and its side effects.
Materials and methods
Among patients who had previous diagnosis and treatment of mild and
minimal endometriosis according to the revised American Fertility
Society (rAFS) classi®cation (The American Fertility Society, 1985),
those with symptoms due to `probable' recurrent endometriosis,
without interest in future child bearing, were considered to be eligible
for the study. After thorough discussion of presacral neurectomy,
percutaneous neurolytic techniques and the laparoscopic neurolytic
technique we were planning to perform with the patients, we did the
®rst laparoscopic presacral neurolysis among those who volunteered
in August 1999.
A total of 15 patients were treated between August, 1999 and June,
2001. All patients were followed for at least 1 year.
At baseline all patients were screened for depressive and anxiety
states by the Hospital Anxiety and Depression Scale (HADS), which is
a self assessment mood scale speci®cally designed for the use of non-
psychiatric hospital outpatients to determine the states of anxiety and
depression (Zigmond and Snaith, 1983). It has been shown to be a
reliable instrument for screening and a valid measure of severity of
these mood disorders in patients under investigation of non-
psychiatric departments. It consists of 14 items, seven for the anxiety
and seven for the depression subscales. Five mutually exclusive
answers are provided for each of the questions; they are rated from 0
to 4 according to increasing psychiatric severity. The points are then
summed to give anxiety and depression subtotals and a total score. In
terms of subscales a score of <7 indicates non psychiatric cases and
>11 indicates psychiatric cases, whereas those in between are regarded
as doubtful. For the validity and reliability of HADS in our population,
the cut of point was found to be 10 and 7 for anxiety and depression
subscales respectively. In this trial only non-psychiatric cases were
considered to be eligible.
In all non-psychiatric cases, diagnostic laparoscopy and potential
presacral neurolysis in patients with rAFS scores <16, were planned in
the ®rst postmenstrual week.
Our aim was to assess the effectiveness of laparoscopic presacral
neurolysis on symptom resolution, on the need of non-opioid analgesic
consumption during menses and on sexual performance. Furthermore
the intraoperative and postoperative complications of presacral
neurolysis were recorded.
To assess the impact of laparoscopic presacral neurolysis on
symptoms, grading of symptoms and physical ®ndings before and
after treatment were done on a previously developed and commonly
used scale (Biberoglu and Behrman, 1981). We have modi®ed the
original scale by excluding the induration. In this modi®ed scale
symptoms of dysmenorrhea, dyspareunia, pelvic pain, and the
physical ®nding pelvic tenderness were each scored by the patient
as: none (0 points), minimal (1), moderate (2) and severe (3). The sum
of these variables comprised the Total Pelvic Symptom Score (TPSS)
in this study.
To assess the impact of laparoscopic presacral neurolysis on the
consumption of non-opioid analgesic use during menses to cope with
dysmenorrhea, all patients were asked to use naproxen sodium 250 mg
tablets twice daily whenever necessary throughout menses. They were
asked to record the number of tablets during the whole period in the
preoperative menstrual period and postoperative menses for 1 year.
Preoperatively all patients completed the questionnaire of the
revised Sabbatsberg Sexual Rating Scale (SSRS) to de®ne the impact
of treatment on sexual functioning. The revised SSRS is a 12 item
questionnaire for the assessment of sexual functioning (Garrat et al.,
1995). For each item, there are ®ve possible answers, scored from 0 to
4 points (from the lowest to the highest sexual satisfaction). The scores
of 12 items are then summed and transformed to a scale of 0 to 100.
This scale is reliable and valid in our patient population and widely
used in clinical trials to assess the impact of interventions on sexual
functioning. This scale is a general measure of sexual functioning for
women and covers both the quantity and quality of sexual experience
whilst being relatively brief and not intrusive. It raises simple
questions regarding interest, sexual activity, sexual pleasure, orgasmic
capacity and importance of sex at present and in the past. Women
experiencing pain with sex have signi®cantly lower sexual rating
scores (Garrat et al., 1995). Our rational was to investigate the impact
of this surgery in increasing sexual performance via decreasing pain.
Keeping the reported complications of presacral neuorectomy in
mind, patients were speci®cally questioned regarding bowel habits
and urinary symptoms (constipation, diarrhoea, stress incontinence,
urge incontinence and voiding dif®culty).
In volunteers, diagnostic laparoscopy was performed in the ®rst
postmenstrual week for rAFS scoring. We performed laparoscopic
presacral neurolysis only in cases with rAFS scores <16 to treat
symptoms. We did not perform any fulguration, excision of
endometriotic foci other than a biopsy for histological con®rmation.
The patients were discharged the day after the procedure and had an
early postoperative visit at the 5th postoperative day.
The technique of laparoscopic presacral neurolysis is a simple one.
A 10 mm umbilical port is used for the standard insuf¯ation and video
endoscopy. Two additional 5 mm subumbilical standard ports are
created for diagnostic and therapeutic purposes. After the diagnostic
laparoscopy for rAFS scoring the promontorium is identi®ed. The
peritoneum overlying the promontorium is grasped and elevated by a
commercially available endoscopic grasper and from the other port,
5 ml of saline was injected retroperitoneally by a commercially
available laparoscopic needle used for ovarian cyst puncture. This
elevates the peritoneum and endopelvic fascia from the promontor-
ium. Furthermore this space avoids inadvertent injection of phenol to
vessels and back¯ow of phenol to the peritoneal space. Then 10 ml
phenol (10% in Urogra®n, radiographic contrast medium; Shering
AG, Germany) is injected slowly to the deeper part of the arti®cially
created retroperitoneal space from another point of entry. Before
withdrawing the needle an additional 2 ml of saline was given to avoid
i.p. spillage of phenol during the withdrawal of the needle. Afterwards
a thorough pelvic lavage was done. The presacral neurolysis itself is a
2 min operation not including the laparoscopic set-up, diagnostic
laparoscopy and drug preparation. For demonstration purposes
¯uoroscopic controls can be used (Figures 1 and 2).
We have used phenol 10% in Urogra®n to achieve neurolysis.
Phenol(carbolic acid) is a neurolytic agent. The solution was prepared
in the operating theatre just before the injection (Raj, 1992). In order to
prepare this solution the following steps were followed: 10 ml of
ethanol 95%, was drawn into a 15 cc disposable plastic syringe, the
needle was removed and a 0.2-mm acid stable ®lter was attached to the
syringe and ethanol was pushed through the syringe on to a 4 3 4 inch
sterile dry gauze pad. Then 5 ml of phenol 89% was drawn into
another sterile glass syringe. The 0.2-mm acid stable ®lter, previously
prepared by ethanol, was attached to this syringe and 0.9 ml of phenol
was slowly pushed into a glass container in order to eliminate the
ethanol residue in the ®lter. Urogra®n came in 30 ml ampoules; 26.7
ml Urogra®n was transferred into a sterile 30 ml vial and 3.3 ml of
89% phenol was added to this vial through the 0.2 mm acid stable ®lter.
The ®nal concentration of phenol was ~10% in this ready-to-use
solution; 10 ml of this solution was used for laparoscopic presacral
neurolysis.
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Patients were re-evaluated at the 3rd, 6th, and 12th month
postoperatively. At each of these visits total pelvic symptom score,
non-opioid analgesic consumption (as the total number of naproxen
sodium 250mg tablets) and SSRS were re-evaluated and noted.
Complications were searched and appropriately treated.
Statistical analysis of this trial was done by InStat software for
Windows (Graph Pad Inc., USA). After performing the descriptive
statistics for our patient population, we have performed repeated
measures of Anova with Tukey as the post test if P < 0.05 to analyse
the impact of intervention on TPSS, SSRS and non opioid analgesic
consumption during the study period. All data passed the normality
tests.
Results
The baseline descriptive statistics of our patient population is
given in Table I. At baseline evaluation only two patients
reported constipation whereas none reported diarrhoea, urinary
incontinence or voiding dif®culty.
The impact of laparoscopic presacral neurolysis on TPSS,
SSRS and the non-opioid analgesic consumption during
menses is given in Table II. Repeated measures of analysis
of variance of main outcome measures during the study period
is presented in Table III. It was evident that laparoscopic
presacral neurolysis was effective in eliminating pelvic symp-
toms, restoring sexual performance and reducing analgesic
need during menses. In each variable the impact of treatment
was evident at the 3rd postoperative month and continued
during the whole follow up period without any signi®cant
change.
We observed no technical dif®culty during the performance
of the laparoscopic presacral neurolysis procedure, noted no
intraoperative and only one early postoperative surgical
complication. The only early postoperative complication was
retention of the urine and it recovered by the 12th postoperative
day without any medication other than clean intermittent self
catheterization. At the 3rd postoperative month evaluation, 11
patients including the previous two complained of constipa-
tion. One patient with baseline constipation worsened. A high
®bre diet with 3 l water plus one small coffee cup of olive oil at
bed time proved to be effective in ten of the patients while the
last patient improved by adding senna in the recommended
dosage at the fourth postoperative month.
Discussion
In our opinion it is particularly necessary to discuss three
important aspects of this study: (i) our rationale behind the
laparoscopic presacral neurolysis; (ii) the technique and its
Figure 2. Lateral ¯uoroscopic view of the presacral retroperitoneal
space that shows the dissemination of the neurolytic in the desired
anatomical site. Arrows: L5 vertebra and promontorium; a = lateral
view of phenol dissemination.
Table I. Baseline clinical characteristics of study subjects
Baseline characteristics Mean (SD)
Age 33.4 (1.9)
Gravida 2.3 (0.8)
rAFS score at laparoscopy 6.4 (2.06)
HADS score
Anxiety 4.5 (1.1)
Depression 3.6 (0.8)
Total 8.2 (1.2)
TPSS 9.0 (1.2)
ACDMa 8.9 (1.1)
SSRS 30.9 (4.3)
aTotal number of naproxen sodium 250mg tablets.
HADS = The Hospital Anxiety and Depression Scale; TPSS = Total Pelvic
Symptom Score; ACDM = Analgesic consumption during menses; SSRS =
The revised Sabbatsberg Sexual Rating Scale
Table II. The impact of presacral neurolysis
Baseline
Mean (SD)
3rd month
Mean (SD)
6th month
Mean (SD)
12th month
Mean (SD)
TPSS 9.06 (1.2) 2.6 (0.9) 2.4 (1.1) 2.2 (0.8)
SSRS 30.9 (2.3) 64.3 (3.2) 64.1 (2.8) 64.2 (2.8)
ACDMa 8.9 (1.1) 2.4 (0.9) 2.2 (1.01) 2.6 (0.8)
aTotal number of naproxen sodium 250 mg tablets during menses.
TPSS = Total Pelvic Symptom Score, SSRS = Sabbatsberg Sexual Rating
Scale; ACDM = Analgesic Consumption During Menses.
Figure 1. 10% 10 ml of phenol in Urogra®n in presacral
retroperitoneal space. Antero-posterior ¯uoroscopic view that shows
the dissemination of the neurolytic in to the desired anatomical
site.1 = L5 vertebra; 2 = dissemination of phenol in Urogra®n.
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potential complications and (iii) our rationale for not treating
the endometriosis itself and not using the laparoscopic
presacral neurolysis as an adjunctive measure.
A signi®cant proportion of patients with endometriosis are
candidates for sympathectomy. Sympathectomy as presacral
neurectomy is not a new idea and dates back to 1899 (Kwok
et al., 2001). In 1990 it was shown that this can be done by
laparoscopy (Perez, 1990). However this operation is an
advanced endoscopic procedure and it carries major surgical
risks even in the hands of experienced surgeons (Chen and
Soong, 1997; Kwok et al., 2001). Neurolysis of superior
hypogastric plexus dates back to 1990. Plancarte from Mexico
city was the ®rst pain specialist that performed posterior
transcutaneous superior hypogastric plexus neurolysis
(Plancarte et al., 1990). Their group of patients were those
with pelvic malignancy at the beginning and it was later shown
by them and others that superior hypogastric plexus neurolysis
was effective in reducing pelvic pain and daily opioid use in
both benign and malignant diseases (Waldman et al., 1991; de
Leon-Casasola et al., 1993; Plancarte et al., 1997; Rosenberg
et al., 1998; de Leon-Casasola, 2000). However their method
was technically dif®cult, required bispatial ¯uoroscopy and
there was an active search in pain literature to simplify the
described technique by alternate ways of approach and
advanced imaging techniques (Waldman et al., 1991;
Cousins and Bridenbaugh, 1998; Stevens et al., 2000; Cariati
et al., 2002). Transvascular approach has been reported
(Cousins and Bridenbaugh, 1998). It was not possible for us
to use the standard technique as gynaecologists. Superior
hypogastric blocks which are technically the same are used in
patients with endometriosis (Wechsler et al., 1995; Kanazi
et al., 1999). One author used this block during laparoscopic
pain mapping in order to select patients for presacral
neurectomy (Steege, 1998). Based on the previous works of
these distinguished authors we have realised that injection of
neurolytic agent under direct vision via laparoscopy to the
presacral retroperitoneal space can be a very simple and
effective form of sympathectomy. During our study period the
simplicity of the procedure for the average gynaecologist was
clearly evident. We noted similar effectiveness as compared
with the literature on neurolysis and neurectomy.
Laparoscopic presacral neurolysis is a very simple operation
for the average gynaecologist. It is merely injecting 10 ml of
neurolytic solution in the retroperitoneal space over the
promontorium. Phenol and alcohol are the principle agents
used for sympathetic neurolysis. Phenol (carbolic acid) is used
extensively in neurolysis, it causes a nonspeci®c destruction on
neural architecture. To date no complications regarding the
superior hypogastric plexus neurolysis with phenol is reported
in more than 200 transdermally performed cases (Cousins and
Bridenbaugh, 1998; de Leon-Casasola, 2000). However poten-
tial theoretical complications that have to be taken into account
in transdermal approach are intramuscular (psoas muscle),
intravascular, subarachnoid, epidural, intraperitoneal, intra-
visceral (bowel, ureter) injections. Neurolytic damage of
somatic nerves can occur with direct needle trauma or with
spillage of neurolytic solutions. Vascular puncture can cause
retroperitoneal haematoma formation. None of these theor-
etically possible complications is reported; however, there are
some universal cautions to exercise (Cousins and Bridenbaugh,
1998). The ®rst is proper needle placement which is checked by
the ¯uoroscopy or advanced imaging in the transdermal
approach. Aspiration for blood is important. Intravascular
injection of phenol may cause tinnitus, ¯ushing, tremors and
convulsions. The recovery is rapid and complete. Unexpected
spread to nearby somatic nerves may cause permanent neural
de®cits. Thus the least possible volume should be chosen. In
the ®rst 15 cases we have treated, we used direct laparoscopic
approach to the presacral space and achieved the exact
anatomic orientation. In other words laparoscopy was the
advanced and ultimate imaging technique of proper place
selection. We were aware of the retroperitoneal location of
major vessels and by raising the peritoneum with retro-
peritoneally injected saline we stayed away from the middle
sacral vein and artery. We were aware of the fact that there was
no somatic nerve in this anatomical location. As we injected
the least possible volume recorded in the literature for this
particular procedure and did not create any weakness of
endopelvic fascia structure, we avoided spillage of the solution.
Furthermore by injection of the solution from another point of
entry, and an additional 2 ml of saline before removal and
through pelvic lavage we avoided i.p. spillage of the agent. We
Table III. Repeated measures analysis of variance during the study period
TPSS SSRS ACDM (Naproxen 250 mg tablets)
Mean
difference
95% CI P-value Mean
difference
95%CI P-value Mean
difference
95% CI P-value
Baseline versus
3rd month
5.733 4.9±6.5 < 0.001 ±33.40 (±)36.4±(±)30.3 < 0.001 6.53 5.5±7.5 < 0.001
Baseline versus
6th month
5.867 5.0±6.6 < 0.001 ±33.21 (±)36.2±(±)30.1 < 0.001 6.73 5.7±7.7 < 0.001
Baseline versus
12th month
5.800 4.9±6.6 < 0.001 ±33.26 (±)36.3± (±)30.2 < 0.001 6.66 5.6±7.6 < 0.001
3rd versus 6th month 0.13 (±)0.6±0.9 ns 0.20 (±)2.8±3.2 ns 0.20 (±)0.8±1.2 ns
3rd versus 12th month 0.06 (±)0.7±0.8 ns 0.13 (±)2.9±3.1 ns 0.13 (±)0.8±1.1 ns
6th versus 12th month ±0.06 (±)0.8±0.7 ns 0.06 (±)3.1±2.9 ns ±0.06 (±)1.0±0.9 ns
TPSS = total pelvic symptom score; SSRS = Sabbatsberg sexual rating scale; ACDM = analgesic consumption during menses; CI = con®dence interval; ns =
not signi®cant.
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observed no intraoperative or postoperative complications
related to the procedure itself. However as the neurolysis was
effective, one patient developed transient urinary retention and
a signi®cant proportion developed constipation as side effects.
These are the recorded side effects of neurolysis and presacral
neurectomy (Chen and Soong, 1997; Nezhat et al., 1998; Perry,
1999).
In the literature it is very dif®cult to know how much credit
to assign to the presacral neurectomy in the relief of
endometriosis symptomatology as the procedure is often
performed in conjunction, as an adjunctive measure, with
other procedures such as fulguration, excision of endometriotic
foci (Kwok et al., 2001). We consider these procedures, as well
as the laparoscopic presacral neurolysis-neurectomy, as a
symptomatic not a causal form of treatment in patients with
endometriosis. Literature also supports the view that endome-
triosis is a dynamic disease that can be progressive, static or
resolving in any given patient (Sutton et al., 1997). Since
currently we are unable to identify those progressive cases in
any given time, we have chosen to treat the symptoms by
neurolysis in minor degrees of endometriosis. This design was
particularly useful to prove the potential impact of laparoscopic
presacral neurolysis on symptom relief attributed to endome-
triosis.
In the study period we noticed how easy it could be to
perform a laparoscopic presacral neurolysis. In our opinion
surgery should be simple but the surgeon should have expertise
and be cautious. Furthermore our results indicated an effective
technique that achieved symptom relief. Most probably due to
its effectiveness on the control of visceral pain, this technique
also decreased analgesic consumption, and improved sexual
performance.
In conclusion, laparoscopic presacral neurolysis is feasible
and easy to perform. Our data indicates that this novel
technique can be considered in the treatment of painful benign
pelvic conditions as the only form of symptomatic treatment or
as an adjunctive procedure. However more data is needed to
support its ef®cacy and safety. We must emphasize the
preliminary nature of the study and we believe randomized
controlled trials are necessary before the procedure becomes
widely adopted.
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